Peter Higgs

Peter Higgs


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002 in International Journal of Drug Policy
Verified
Journal Article
Closed access
CACampbell Aitken
Campbell Aitken
DMDavid Moore
David Moore
PHPeter Higgs
Peter Higgs
JKJenny Kelsall
Jenny Kelsall
MKMichael Kerger
Michael Kerger

28 August 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
MHMargaret Hellard
Margaret Hellard
DRDavid A Rolls
David A Rolls
RSRachel Sacks‐Davis
Rachel Sacks‐Davis
GRGarry Robins
Garry Robins
PPPhilippa Pattison
Philippa Pattison
EMEmma McBryde
Emma McBryde
With the development of new highly efficacious direct-acting antiviral (DAA) treatments for hepatitis C virus (HCV), the concept of treatment as prevention is gaining credence. To date, the majority of mathematical models assume perfect mixing, with injectors having equal contact with all other injectors. This article explores how using a networks-based approach to treat people who inject drugs (PWID) with DAAs affects HCV prevalence. Using observational data, we parameterized an exponential random graph model containing 524 nodes. We simulated transmission of HCV through this network using a discrete time, stochastic transmission model. The effect of five treatment strategies on the prevalence of HCV was investigated; two of these strategies were (1) treat randomly selected nodes and (2) “treat your friends,” where an individual is chosen at random for treatment and all their infected neighbors are treated. As treatment coverage increases, HCV prevalence at 10 years reduces for both the high- and low-efficacy treatment. Within each set of parameters, the treat your friends strategy performed better than the random strategy being most marked for higher-efficacy treatment. For example, over 10 years of treating 25 per 1,000 PWID, the prevalence drops from 50% to 40% for the random strategy and to 33% for the treat your friends strategy (6.5% difference; 95% confidence interval: 5.1-8.1). Conclusion: Treat your friends is a feasible means of utilizing network strategies to improve treatment efficiency. In an era of highly efficacious and highly tolerable treatment, such an approach will benefit not just the individual, but also the community more broadly by reducing the prevalence of HCV among PWID. (Hepatology 2014;60:1860–1869)

1 February 2021 in International Journal of Dental Hygiene
Verified
Journal Article
Closed access
PDF file
KBKamal Baniasadi
Kamal Baniasadi
BABahram Armoon
Bahram Armoon
PHPeter Higgs
Peter Higgs
ABAmir‐Hossein Bayat
Amir‐Hossein Bayat
MGMohammad Ali Mohammadi Gharehghani
Mohammad Ali Mohammadi Gharehghani
RSRobert J. Schroth
Robert J. Schroth

10 February 2020 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
MYMohsen Yazdanian
Mohsen Yazdanian
BABahram Armoon
Bahram Armoon
ANAlireza Noroozi
Alireza Noroozi
RMRasool Mohammadi
Rasool Mohammadi
ABAmir-Hosein Bayat
Amir-Hosein Bayat
MHMorteza Hemmat
Morteza Hemmat
Background: The aim of our study was to perform a systematic review of the literature and meta-analysis in order to investigate relationship between drug use and oral health. Methods: We searched for studies in English published before July 1, 2019 on PsycINFO, PubMed, SciELO, Scopus, and Web of Science. We assessed the relationship between drug use (methamphetamines, heroin; opiates; crack, cocaine and cannabis as dependent variables) and reported tooth loss, periodontal disease, or decayed, missing, and filled teeth index as an independent variable. The data were analyzed using Stata 12.0 software. Results: We initially identified 1836 potential articles (with 1100 duplicates) and screened the remaining 736 titles and abstracts, comprising 54 studies. In the next step, we evaluated the full-texts; 44 studies were excluded, accordingly. In total, we included 10 publications in the meta-analysis. Drug type was associated with periodontal disease (OR 1.44; 95% CI 0.8–2.6) and pooled estimates showed that type of drug used increased the odds of the number of decayed, missed and filled teeth (DMFT) (OR 4.11; 95% CI 2.07–8.15) respectively. Conclusions: The analytical challenges of segregating the impact of individual drug types on oral health diseases mean that investigations on the direct relationship between oral health status and drug use are limited. Developing programs to improve potential confounding with various substances and addressing the dental health needs of people who use drugs is vital if we are to improve their overall quality of life.

1 January 2013 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
DHDanielle Horyniak
Danielle Horyniak
PHPeter Higgs
Peter Higgs
RJRebecca Jenkinson
Rebecca Jenkinson
LDLouisa Degenhardt
Louisa Degenhardt
MSMark Stoové
Mark Stoové
PDPaul Dietze
Paul Dietze
Cohort studies provide an excellent opportunity to monitor changes in behaviour and disease transmission over time. In Australia, cohort studies of people who inject drugs (PWID) have generally focused on older, in-treatment injectors, with only limited outcome measure data collected. In this study we specifically sought to recruit a sample of younger, largely out-of-treatment PWID, in order to study the trajectories of their drug use over time.

26 October 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RSRachel Sacks-Davis
Rachel Sacks-Davis
GDGalina Daraganova
Galina Daraganova
CACampbell Aitken
Campbell Aitken
PHPeter Higgs
Peter Higgs
LTLilly Tracy
Lilly Tracy
MHMargaret Hellard
Margaret Hellard
It is hypothesized that social networks facilitate transmission of the hepatitis C virus (HCV). We tested for association between HCV phylogeny and reported injecting relationships using longitudinal data from a social network design study. People who inject drugs were recruited from street drug markets in Melbourne, Australia. Interviews and blood tests took place three monthly (during 2005–2008), with participants asked to nominate up to five injecting partners at each interview. The HCV core region of individual isolates was then sequenced and phylogenetic trees were constructed. Genetic clusters were identified using bootstrapping (cut-off: 70%). An adjusted Jaccard similarity coefficient was used to measure the association between the reported injecting relationships and relationships defined by clustering in the phylogenetic analysis (statistical significance assessed using the quadratic assignment procedure). 402 participants consented to participate; 244 HCV infections were observed in 238 individuals. 26 genetic clusters were identified, with 2–7 infections per cluster. Newly acquired infection (AOR = 2.03, 95% CI: 1.04–3.96, p = 0.037, and HCV genotype 3 (vs. genotype 1, AOR = 2.72, 95% CI: 1.48–4.99) were independent predictors of being in a cluster. 54% of participants whose infections were part of a cluster in the phylogenetic analysis reported injecting with at least one other participant in that cluster during the study. Overall, 16% of participants who were infected at study entry and 40% of participants with newly acquired infections had molecular evidence of related infections with at least one injecting partner. Likely transmission clusters identified in phylogenetic analysis correlated with reported injecting relationships (adjusted Jaccard coefficient: 0.300; p<0.001). This is the first study to show that HCV phylogeny is associated with the injecting network, highlighting the importance of the injecting network in HCV transmission.